Pfizer and BioNTech ’companies state that three injectable doses of the vaccine are capable of offering high protection against the Omicron Covid-19 variant. Preliminary studies found that a booster dose of the vaccine could increase the body’s resistance by 25 -fold compared to a series of two initial doses.
Booster injections showed pandemic-fighting abilities comparable to the 95% protection provided by two doses against the original strain of Covid-19. The company states two doses of the vaccine are able to reduce Omicron attacks and neutralize them.
Pfizer CEO Albert Bourla in a joint statement with BioNTech stated that “While two doses of the vaccine may still offer protection against chronic diseases caused by the Omicron strain, early studies of booster injections could enhance even greater protection”.
Bourla added by encouraging the general public who have yet to get a two-dose vaccination to get it along with a booster dose as it is the best course of action to prevent Covid-19 transmission.
Be informed that Pfizer and BioNTech are working to record similar results in the initial study for a period of one or two weeks. It was also noted that the Pfizer company will have enough data by the end of the month to determine whether the booster dose is enough to fight omicron or if a new vaccine is needed.
Although scientists believe that omicrons spread faster, they have said that more data are needed to determine the correlation of diseases caused by such variants.
